ModeX Therapeutics Awarded Contract to Address Public Health Threat From Viral Diseases
By Denny Jacob
ModeX Therapeutics, a OPKO Health company, was awarded a contract hailing from the Biomedical Advanced Research and Development Authority to advance candidates designed to address a range of public health threats in viral infectious diseases.
The clinical-stage biopharmaceutical company said the awarded funding would enable research, development and clinical evaluation of multispecific antibodies based on its proprietary technology.
The contract includes an initial $59 million for the development and execution of a clinical trial for a multispecific antibody with broad neutralizing abilities against known variants of the coronavirus known as SARS-CoV-2. Additional funding of up to $109 million may be available upon hitting certain milestones.
The Biomedical Advanced Research and Development Authority is part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
September 28, 2023 16:55 ET (20:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom